| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.054 | 0.07 |
| mRNA | CAY10618 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.07 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.059 | 0.08 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.08 |
| mRNA | A-443654 | GDSC1000 | pan-cancer | AAC | -0.091 | 0.08 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.08 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.084 | 0.08 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | -0.088 | 0.08 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.059 | 0.08 |